Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Belief BioMed Signs up Takeda to Commercialize Gene Therapy for Hemophilia in China

publication date: Oct 19, 2023

Shanghai Belief BioMed sold China commercialization rights to Takeda China for its lead candidate, BBM-H901, an adeno-associated virus (AAV)-based AAV gene therapy for hemophilia B, a rare disease. The candidate delivers the missing human factor Ⅸ (FⅨ) gene into the body intravenously and is expected to be effective for a “long time,” though BBM isn’t specific. In April of this year, BBM completed dosing adult patients in a China Phase III trial of BBM-H901. Takeda China will have an exclusive commercialization license for BBM-H901 in mainland China, Hong Kong and Macau. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital